# AvantGuard

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avantguard

- Industry: Chemicals
- Headquarters: Ithaca, US
- Website: www.avantguardinc.com
- Total disclosed funding: $1.2M
- Latest round: Seed (May 11, 2023)
- Investors on record: 4

## About

AvantGuard, Inc., based in New York, US, develops pioneering antimicrobial technologies. Their key product, Avantamine™, effectively combats pathogens while minimizing resistance, serving critical sectors like healthcare and food safety.AvantGuard, Inc. is dedicated to creating advanced antimicrobial solutions, with its headquarters located in Ithaca, US. Founded in 2018 by Greg Bertsch, the company has executed a total of 6 deals, the most recent being a Seed round on May 11, 2023, raising USD 1.23 mn from investors including Blue Ledge Capital, Launch NY, Red Bear Angels Management, and SOSV. The cumulative funding raised by AvantGuard amounts to USD 1.23 mn, with a current company valuation of USD 44.96 mn.AvantGuard specializes in developing innovative antimicrobial technologies, with Avantamine™ as its flagship product. This molecule uniquely mimics the body's immune response to target bacteria, viruses, and fungi, and can be used as an antiseptic, disinfectant, or surface coating. Avantamine™ finds significant applications in healthcare settings, aiming to reduce life-threatening infections in vulnerable populations, and is marketed primarily in North America to healthcare facilities, medical device manufacturers, and the food and beverage industry.AvantGuard operates on a revenue model that focuses on B2B transactions, providing antimicrobial solutions through direct sales to hospitals and medical facilities in critical need of infection control. Their offerings, including Avantamine™, are sold via bulk orders and supply agreements, with pricing reflecting the advanced technology's value in improving health outcomes and minimizing costs linked to hospital-acquired infections.Following the Seed funding raised on May 11, 2023, AvantGuard plans to utilize the USD 1.23 mn to enhance the development of its antimicrobial technologies, expand its team by hiring more scientists, and broaden its global market presence. Specific target regions and new product launches will be further defined as the company progresses with its growth initiatives.

## Funding rounds

- Seed, May 11, 2023, $1.2M — SOSV, Launch NY, Red Bear Angels Management, Blue Ledge Capital
- Seed, Jun 24, 2020 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- Launch NY (https://capitalatlas.ai/funds/launch-ny) — Seed
- Red Bear Angels Management — Seed
- Blue Ledge Capital (https://capitalatlas.ai/funds/blue-ledge-capital) — Seed